Ajay Bagga offers a clear strategy for Indian markets. He advises waiting for real AI revenue in IT. Pharma remains a strong investment due...

Benchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent ...

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

Indian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...

Indian equity benchmarks closed modestly higher on Friday, with financial stocks leading the gains. The Nifty and Sensex edged up, though p...

Indian equity markets fell for a fourth straight session as rising crude oil prices, geopolitical tensions, FII selling, and a record-low r...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

As innovation evolves beyond industry boundaries, the AI Special Product / Innovation category at the ET Most Innovative AI Product Awards ...

Despite Middle East tensions and a sliding Nifty50, India's smallcap stocks have surged up to 56% in two months. While institutional desks ...

The ET Most Innovative AI Product Awards 2026 brings together 11 distinct categories that reflect where artificial intelligence is deliveri...

This is the first time ever that an NDA from a new chemical entity (NCE) from an Indian pharma company has been filed and accepted by the U...

Bayer, the renowned pharmaceutical powerhouse from Germany, is implementing a tiered pricing strategy on a global scale to make medications...

Alembic Pharma on Tuesday said its associate company Rhizen Pharmaceuticals AG's product Umbralisib, which was licensed to TG Therapeutics,...

A global non-profit drug developer TB Alliance has tied up with domestic company Macleods Pharmaceuticals to develop and commercialise its ...

All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquis...

The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme.

Indian pharma majors may manage to market their first indi-genous "blockbuster drugs" or new chemical entities (NCEs) in the next four year...